Personalis at 2021 Neoantigen Based Therapies Summit US: OCT 26-28, 2021


Christelle Johnson

Christelle Johnson, PhD
Senior Field Application Scientist
Cancer Genomics & Immuno-Oncology
Personalis, Inc.

OCT 26-28  

ImmunoID NeXT: A Comprehensive Platform for Immuno-Oncology – Improving Neoantigen Prediction, Evaluating Tumor Dynamics, and Immunogenomics Profiling

  • Accurate assessment of mutational landscape and putative neoantigens from the analytically-validated exome and transcriptome ImmunoID NeXT platform
  • Improved neoantigen presentation and binding predictions through a machine learning algorithm, SHERPA, built upon high quality immunopeptidomics training data from mono-allelic, and multi-allelic samples
  • Comprehensive immunogenomics profiling from a single sample to guide neoantigen-based therapies and biomarker discovery

Connect with us at 2021 Neoantigen Based Therapies Summit US